How to Get Jardiance in Arizona: Telehealth, Prescriptions, and Pharmacy Access

What Jardiance Is and Why Arizona Patients Seek It

Empagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney's proximal tubule, lowering blood sugar while simultaneously reducing intraglomerular pressure and plasma volume. The FDA first approved Jardiance for type 2 diabetes management in August 2014, subsequently adding a cardiovascular risk-reduction indication in December 2016, a heart failure indication in 2021, and a chronic kidney disease (CKD) indication in 2023. [1] [2]

The EMPA-REG OUTCOME trial (N=7,020 patients with type 2 diabetes and established cardiovascular disease) found that empagliflozin 10 mg or 25 mg daily reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (hazard ratio 0.86; 95% CI 0.74, 0.99; P<0.001 for non-inferiority, P=0.04 for superiority). [3] Cardiovascular death specifically fell by 38% (HR 0.62; 95% CI 0.49, 0.77; P<0.001). [3]

The EMPEROR-Reduced trial (N=3,730) confirmed a 25% reduction in the composite of cardiovascular death or heart failure hospitalization in patients with heart failure and reduced ejection fraction (HR 0.75; 95% CI 0.65, 0.86; P<0.001). [4] The EMPA-KIDNEY trial (N=6,609) showed a 28% reduction in the primary kidney disease progression endpoint for patients with CKD (HR 0.72; 95% CI 0.64, 0.82; P<0.001). [5]

Arizona sees meaningful demand for SGLT2 inhibitors because the state's adult obesity prevalence is approximately 31.2% and its diagnosed type 2 diabetes prevalence is around 11.4%, both per CDC surveillance data. [6] Access through telehealth has grown substantially since Arizona amended its telemedicine statute under A.R.S. § 36-3602 to require insurers to cover telehealth services at parity with in-person visits.

Who Can Prescribe Jardiance in Arizona

Any Arizona-licensed prescriber with full prescriptive authority can write for empagliflozin. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs).

Arizona is a full-practice-authority state for NPs under A.R.S. § 32-1606, meaning a certified NP can prescribe Schedule II, V controlled substances and non-controlled drugs, including empagliflozin, without a supervising physician co-signature. [7] PAs in Arizona operate under a supervision agreement but retain independent prescribing authority for non-controlled medications once the agreement is on file with the Arizona Medical Board.

The prescriber does not need to specialize in endocrinology or cardiology. Primary care physicians, internal medicine physicians, family nurse practitioners, and adult-gerontology NPs routinely initiate Jardiance. Subspecialists such as nephrologists and cardiologists often continue or adjust the prescription after referral.

Telehealth prescribing follows the same rules: the provider must hold an active Arizona license, must perform a clinical evaluation sufficient to establish a valid prescriber-patient relationship, and must document that evaluation in a medical record. Arizona does not require a prior in-person visit before a telehealth provider prescribes a non-controlled medication. Empagliflozin is not a controlled substance, so a telehealth prescription is fully permissible on a first visit, provided the provider conducts an adequate history and reviews pertinent labs. [8]

Lab Work Required Before a Jardiance Prescription in Arizona

Most Arizona prescribers order the same core panel before initiating empagliflozin. The FDA label specifies that Jardiance should not be started in patients with an eGFR <20 mL/min/1.73 m² and that the drug's glucose-lowering efficacy diminishes below eGFR 45 mL/min/1.73 m². [1]

Standard pre-prescription labs include:

• eGFR / serum creatinine. Establishes kidney function baseline; determines whether the diabetes glucose-lowering indication is appropriate.
• HbA1c. Documents glycemic control for diagnosis and prior authorization.
• Basic metabolic panel (BMP). Screens for electrolyte abnormalities and confirms serum potassium before initiating a drug that can mildly raise potassium.
• Urinalysis with urine albumin-to-creatinine ratio (UACR). Required for the CKD indication (UACR >200 mg/g with eGFR 20, 45) and useful for cardiovascular risk stratification.
• Blood pressure. Empagliflozin produces a modest blood pressure reduction (approximately 3 to 4 mmHg systolic in EMPA-REG OUTCOME); baseline BP informs dose decisions for patients already on antihypertensives. [3]

Most Arizona commercial labs (Quest Diagnostics, Labcorp, Sonora Quest) can complete a BMP plus HbA1c within 24 to 48 hours. Telehealth platforms often send lab orders digitally so patients can walk into any in-network draw site in Phoenix, Tucson, Scottsdale, Mesa, or rural Arizona locations.

The American Diabetes Association's 2024 Standards of Care specify that eGFR monitoring should occur at baseline, at three months after initiation, and then annually for stable patients. [9] Prescribers in Arizona generally follow this schedule.

How Telehealth Providers in Arizona Prescribe Jardiance

Arizona telehealth platforms that prescribe empagliflozin follow a standardized intake-to-prescription workflow that typically takes two to seven business days from registration to a pharmacy-ready prescription.

A representative workflow looks like this:

1. Intake form. The patient completes a medical history covering diabetes diagnosis date, current medications, prior cardiovascular events, and kidney disease history.
2. Lab order. The platform sends an electronic lab requisition to a draw site near the patient.
3. Clinical review. A licensed Arizona prescriber reviews the labs, intake form, and any uploaded records.
4. Synchronous or asynchronous visit. Arizona law permits asynchronous (store-and-forward) telehealth for non-controlled prescription drugs, so the prescriber may finalize the prescription without a live video call if the documentation is sufficient. [8]
5. E-prescription. The prescription is sent electronically to the patient's preferred Arizona pharmacy or to a mail-order pharmacy licensed to ship into Arizona.

Arizona's parity law (A.R.S. § 20-1057.13) requires commercial insurers to reimburse telehealth visits for covered services at the same rate as in-person visits. Patients covered by Blue Cross Blue Shield of Arizona, UnitedHealthcare Arizona, Cigna Arizona, or Aetna Arizona plans should verify that their specific plan includes telehealth-delivered chronic disease management as a covered benefit before scheduling.

Insurance Coverage and Prior Authorization in Arizona

Getting commercial insurance to pay for Jardiance in Arizona almost always requires prior authorization (PA). The standard PA documentation includes: [10]

• Current HbA1c value (typically required to be >7.0% for the diabetes indication)
• Documentation of at least one prior trial of metformin (unless metformin is contraindicated)
• eGFR result showing kidney function within the approved prescribing range
• ICD-10 diagnosis codes (E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD)
• Clinical notes confirming the prescriber's assessment

Blue Cross Blue Shield of Arizona's 2024 formulary places empagliflozin on Tier 3, which means a PA is required before any benefit applies. Aetna Arizona requires documentation of HbA1c above 7.0% plus failure of or contraindication to metformin for the diabetes indication. For the heart failure and CKD indications, some plans skip the metformin step-therapy requirement because those are distinct FDA-approved indications not dependent on glycemic control.

Arizona Medicaid (AHCCCS) does not currently cover Jardiance under any covered indication, as of mid-2025. Patients on AHCCCS should ask their prescriber about Boehringer Ingelheim's Lilly Cares patient assistance program, which provides free Jardiance to qualifying low-income patients who do not have other prescription coverage. [11]

The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Management Algorithm states: "In patients with type 2 diabetes and established ASCVD, HF, or CKD, an SGLT2 inhibitor with proven cardiovascular or renal benefit should be used regardless of HbA1c level or background therapy." [12] This language has been useful in Arizona PA appeals where insurers have initially denied Jardiance on glycemic grounds alone in patients prescribed it for heart failure or CKD.

Arizona Pharmacy Options: Retail, Mail-Order, and 503A Compounding

Retail pharmacies. Jardiance is stocked by most major Arizona retail chains: CVS, Walgreens, Fry's Food and Drug (Kroger), Costco, and Walmart pharmacies. Independents in Phoenix, Tucson, Flagstaff, and Yuma generally order it within one business day if not on the shelf.

Mail-order pharmacies. Express Scripts, CVS Caremark, and OptumRx all ship to Arizona addresses. Specialty mail-order pharmacies such as Blink Health and Amazon Pharmacy also dispense Jardiance to Arizona. Shipping takes two to five business days.

503A compounding pharmacies. Arizona-licensed 503A compounding pharmacies are permitted to compound empagliflozin for individual patients when a prescriber documents a clinical need that the commercially available product does not meet (for example, a patient with a documented allergy to a tablet excipient, or a need for a suspension formulation for dysphagia). The FDA distinguishes 503A pharmacies (patient-specific compounding, state-licensed) from 503B outsourcing facilities (bulk compounding for office use). [13] Empagliflozin is not on the FDA's 503B drug shortage list as of mid-2025, so 503B bulk compounding is not a compliant pathway. Arizona 503A pharmacies do compound empagliflozin for individual prescriptions with appropriate clinical documentation.

Cost without insurance. The retail cash price for Jardiance 10 mg (30 tablets, a one-month supply) is approximately $550, $650 at Arizona retail pharmacies in 2025. GoodRx and similar discount programs bring this to approximately $400, $480 at some locations. The Jardiance Savings Card from Boehringer Ingelheim/Lilly can reduce cost-sharing to as low as $10 per month for commercially insured patients who qualify. [11]

How to Transfer a Jardiance Prescription to Arizona

Patients relocating to Arizona from another state can transfer their Jardiance prescription directly in most situations.

A valid out-of-state prescription for a non-controlled drug can be transferred to an Arizona pharmacy one time under Arizona pharmacy law (A.A.C. R4-23-402). The receiving Arizona pharmacist contacts the original pharmacy, verifies the prescription, and dispenses the remaining authorized refills. This transfer is typically same-day.

If the original prescription has no remaining refills, the patient must obtain a new prescription from an Arizona-licensed provider. A telehealth visit with an Arizona-licensed prescriber can produce a new prescription the same day, provided the patient's labs are current (within three to six months is typical). Patients should bring or upload their most recent HbA1c, eGFR, and creatinine results to speed the process.

Prescriptions from Arizona providers can also be sent electronically to out-of-state mail-order pharmacies licensed in Arizona, so patients who have established care with an Arizona telehealth provider may continue filling at their existing mail-order pharmacy without interruption.

Dosing and Titration: What to Expect

The FDA-approved starting dose for all indications is empagliflozin 10 mg once daily, taken in the morning with or without food. [1] For the type 2 diabetes glycemic indication, the dose may be increased to 25 mg once daily if the patient tolerates 10 mg and requires additional HbA1c reduction. For the heart failure and CKD indications, the target and maintenance dose is 10 mg once daily; increasing to 25 mg provides no additional cardiovascular or renal benefit in the EMPEROR-Reduced and EMPA-KIDNEY data sets. [4] [5]

The drug should be held before any surgical procedure involving general anesthesia or significant fluid restriction because of the risk of euglycemic diabetic ketoacidosis (EDKA). The FDA label recommends holding empagliflozin at least three days before elective surgery. [1] Arizona prescribers typically include this instruction in the patient education summary provided at the time of prescribing.

Patients starting Jardiance should expect a modest increase in urination frequency in the first one to two weeks as the drug increases urinary glucose and sodium excretion. Genital mycotic infections occur in approximately 4.8% of women and 3.1% of men in clinical trials; patients should be counseled to maintain genital hygiene and report symptoms promptly. [1]

Managing Costs When Insurance Denies Coverage

When AHCCCS denies coverage and commercial PA is declined on first submission, Arizona patients have several options.

First, the prescriber can submit a peer-to-peer review request, in which the prescribing clinician speaks directly with the plan's medical director. Peer-to-peer reviews overturn initial denials in a significant proportion of cases when the clinical documentation specifically cites EMPA-REG OUTCOME and EMPA-KIDNEY outcomes data and the AACE guideline language quoted above. [12]

Second, patients can file a formal appeal with documentation citing the clinical evidence. Arizona's Department of Insurance and Financial Institutions (DIFI) oversees commercial insurer appeals and requires a decision within 72 hours for urgent (expedited) appeals.

Third, patient assistance programs are available. Boehringer Ingelheim's myBI Support program provides free Jardiance to patients with household incomes at or below 400% of the federal poverty level who lack adequate prescription coverage. [11] Applications are submitted through the prescriber's office or online at the manufacturer's portal.

Fourth, GoodRx Gold and similar discount programs reduce out-of-pocket cost at participating Arizona pharmacies to approximately $380, $430 per 30-tablet supply for Jardiance 10 mg, based on 2025 pricing data.

What the Evidence Says About Empagliflozin's Kidney and Heart Benefits

The 2023 EMPA-KIDNEY trial enrolled 6,609 adults with CKD across a wide eGFR range (eGFR 20, 44 regardless of UACR, or eGFR 45, 89 with UACR at least 200 mg/g). Empagliflozin 10 mg daily reduced the primary endpoint of kidney disease progression or cardiovascular death by 28% (HR 0.72; 95% CI 0.64, 0.82; P<0.001). [5] The benefit was consistent across patients with and without type 2 diabetes, which significantly expanded the population who can benefit.

The EMPEROR-Preserved trial (N=5,988) showed that empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization in patients with heart failure and preserved ejection fraction (HFpEF; EF 40% or higher) by 21% (HR 0.79; 95% CI 0.69, 0.90; P<0.001). [14] This was among the first therapies to show statistically significant benefit in HFpEF, which is particularly common in older women.

The American College of Cardiology / American Heart Association 2022 Heart Failure Guideline gives SGLT2 inhibitors a Class I (Level of Evidence A) recommendation for patients with heart failure and mildly reduced or preserved ejection fraction to decrease hospitalizations and cardiovascular death. [15] Arizona cardiologists and heart failure specialists routinely use this guideline recommendation in PA appeals.

The 2023 KDIGO Clinical Practice Guidelines for Diabetes Management in CKD recommend SGLT2 inhibitors as first-line kidney-protective therapy for patients with type 2 diabetes and CKD who have eGFR at or above 20 mL/min/1.73 m². [16] Arizona nephrologists and primary care providers following KDIGO guidelines will initiate or continue empagliflozin even at lower eGFR ranges than previously recognized.

Practical Timeline: From Decision to First Dose in Arizona

For a patient starting from scratch with no prior diagnosis workup:

• Day 1. Complete telehealth intake form; lab order sent to Sonora Quest or preferred draw site.
• Day 2, 3. Lab draw; results returned to platform within 24 to 48 hours.
• Day 3, 5. Prescriber reviews results, conducts visit (synchronous or asynchronous), sends e-prescription to preferred Arizona pharmacy.
• Day 4, 7. Pharmacy dispenses; patient picks up or receives mail delivery.

For a patient with current labs (within three to six months) already on file:

• Day 1. Telehealth visit with Arizona prescriber; e-prescription sent same day.
• Day 1, 2. Pharmacy dispensing; many Arizona retail pharmacies fill within two to four hours.

The fastest path is a telehealth platform with in-house clinical review and a prior authorization team that can initiate the PA process simultaneously with the prescription.